In a study published in EMBO Journal, researchers at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany, developed nanobodies that efficiently block the coronavirus SARS-CoV-2 and its variants. The high resolution structural characterization was performed at the X10SA crystallography beamline at the Swiss Light Source.
In a study published in Nature Communications, researchers at the NHC Key Laboratory of Systems Biology of Pathogens in Beijing, China, in collaboration with the Paul Scherrer Institut characterize the interactions of SARS-CoV-2 orf9b and human TOM70 biochemically, and they determine the 2.2 Å crystal structure of the TOM70 cytosolic domain with a bound SARS-CoV-2 orf9b peptide.
Health InnovationMedical ScienceResearch on Covid-19
Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.
Research Using Synchrotron LightLarge Research FacilitiesBiologyHealth InnovationResearch on Covid-19
At PSI, researchers are screening molecule fragments to see if these bind to important proteins of the coronavirus SARS-CoV-2 and thus have the potential to disable it. They are hoping the many individual pieces of information will yield an answer as to what an effective drug might look like.
Research Using Synchrotron LightBiologyHealth InnovationResearch on Covid-19
Frankfurt scientists identify a possible weakness of the SARS-CoV-2 virus. They carried out part of their measurements at PSI's Swiss Light Source SLS. The research results are published this week in the scientific journal Nature.
The Dikic group at the Goethe University in Frankfurt am Main, Germany has published the first results following the opening of the "PRIORITY COVID-19 Call” at SLS.
On January 30th, 2020, the WHO declared the recent outbreak of coronavirus disease 2019 (COVID-19), a public health emergency of international concern. It declared that there is an urgent need to improve our understanding of the newly identified virus and its possible future evolution as well as to contain the spread; to develop precise diagnostics and treatment, and to improve the public health response and patient care.
The COVID priority access call continues and is still open in 2022.
